Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Harmony Biosciences Holdings Inc (NASDAQ: HRMY) closed the day trading at $33.49 down -4.10% from the previous closing price of $34.92. In other words, the price has decreased by -$4.10 from its previous closing price. On the day, 0.75 million shares were traded. HRMY stock price reached its highest trading level at $34.9389 during the session, while it also had its lowest trading level at $33.33.
Ratios:
For a better understanding of HRMY, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.65 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 8.67. For the most recent quarter (mrq), Quick Ratio is recorded 3.20 and its Current Ratio is at 3.24. In the meantime, Its Debt-to-Equity ratio is 0.38 whereas as Long-Term Debt/Eq ratio is at 0.28.
On September 10, 2024, UBS started tracking the stock assigning a Buy rating and target price of $56.
On June 21, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $48.Citigroup initiated its Buy rating on June 21, 2024, with a $48 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 01 ’24 when Valor IV Pharma Holdings, LLC sold 4,000,000 shares for $30.30 per share. The transaction valued at 121,210,000 led to the insider holds 7,218,033 shares of the business.
Valor IV Pharma Holdings, LLC sold 600,000 shares of HRMY for $18,181,500 on Nov 05 ’24. The 10% Owner now owns 6,618,033 shares after completing the transaction at $30.30 per share. On Nov 01 ’24, another insider, Marshman Fund Trust II, who serves as the 10% Owner of the company, sold 4,000,000 shares for $30.30 each. As a result, the insider received 121,210,000 and left with 6,651,120 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HRMY now has a Market Capitalization of 1991533184 and an Enterprise Value of 1684744192. As of this moment, Harmony’s Price-to-Earnings (P/E) ratio for their current fiscal year is 15.85, and their Forward P/E ratio for the next fiscal year is 10.53. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.62. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.80 while its Price-to-Book (P/B) ratio in mrq is 3.20. Its current Enterprise Value per Revenue stands at 2.471 whereas that against EBITDA is 8.442.
Stock Price History:
Over the past 52 weeks, HRMY has reached a high of $41.61, while it has fallen to a 52-week low of $28.14. The 50-Day Moving Average of the stock is -4.14%, while the 200-Day Moving Average is calculated to be 1.44%.
Shares Statistics:
Over the past 3-months, HRMY traded about 750.51K shares per day on average, while over the past 10 days, HRMY traded about 415170 shares per day. A total of 57.03M shares are outstanding, with a floating share count of 40.49M. Insiders hold about 29.00% of the company’s shares, while institutions hold 66.01% stake in the company. Shares short for HRMY as of 1731628800 were 5798106 with a Short Ratio of 7.73, compared to 1728950400 on 7452511. Therefore, it implies a Short% of Shares Outstanding of 5798106 and a Short% of Float of 44.849998.
